Company Overview
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education, and brand awareness services; and marketing and channel data services. It also provides 1 Pharmacy online wholesale pharmacy that offers pharmaceutical and other health and wellness products; and 1 Medicine Marketplace online retail pharmacy that provides drugs, nutritional supplements, medical supplies and devices, personal care, and baby products. In addition, the company offers online loan application services; cloud-based inventory management services; smart procurement services, which collect pharmacies' historical purchase orders and inventory data; and Hawkeye automated salesforce tool, as well as online consultation, e-prescription, and data services. Further, its pharmacies provide drugs, including prescription and over-the-counter drugs comprising Western and Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices that consists of bandages and thermometers; and personal care products that include skin care, birth control, sexual wellness, and baby products. Additionally, the company offers research and development, and consulting services; warehousing, procurement, and logistics services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies, medical professionals, and marketplace sellers. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Why Investors Should Care
Net profit has compounded at 28.0% per year over the last five years.
Recent Developments
- Dec 2025 Revenue of $12.56B (-12.8% YoY); net profit $-66.39M.
- Trailing 12 Months Year-on-year growth — revenue -33.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -2.4%, profit CAGR 28.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -2.43% |
| 1 Year: | -33.10% |
Compounded Profit Growth
| 5 Years: | 28.02% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -44.36% |
| 6 Months: | -25.53% |
| 3 Months: | -37.90% |
| 1 Month: | -7.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 28.0% over 5 years.
CONS
- Revenue declined at -2.4% CAGR over 5 years.
- Trading 54.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | YI 111, Inc. | 3.85 | -0.50 | $33.87M | 0.00% | 5.30% | -14.84% | -2.43% | 28.02% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 3.53B | 3.21B | 3.00B | 2.82B | 2.36B |
| Cost of Revenue | - | 3.33B | 3.02B | 2.82B | 2.66B | 2.24B |
| Gross Profit | - | 195.09M | 185.38M | 178.03M | 164.90M | 125.96M |
| Operating Expenses | - | 194.95M | 185.28M | 180.33M | 165.22M | 145.92M |
| Operating Income | - | 145.00K | 95.00K | -2.30M | -321.00K | -19.97M |
| EBITDA | - | 1.44M | 1.19M | 5.60M | 4.84M | -18.94M |
| Interest Expense | - | 8.73M | 8.46M | 7.05M | 11.33M | 7.86M |
| Pretax Income | - | -7.29M | -7.27M | -1.45M | -6.49M | -26.80M |
| Tax Provision | - | 16.00K | -3.00K | 0 | 0 | 0 |
| Net Income | - | -17.65M | -19.55M | -12.97M | -16.22M | -37.04M |
| Diluted EPS | - | -40.00 | -2.20 | -28.00 | -36.00 | -84.00 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 13.52B | 14.95B | 14.40B | 12.56B |
| Cost of Revenue | 12.68B | 14.10B | 13.57B | 11.83B |
| Gross Profit | 839.98M | 848.98M | 829.23M | 723.41M |
| Operating Expenses | 1.21B | 1.20B | 827.12M | 725.78M |
| Operating Income | -371.00M | -350.10M | 2.11M | -2.38M |
| EBITDA | -321.81M | -311.26M | 24.62M | 24.91M |
| Interest Expense | 13.44M | 20.14M | 28.33M | 35.57M |
| Pretax Income | -376.07M | -353.18M | -20.68M | -22.50M |
| Tax Provision | 0 | 251.00K | 96.00K | 13.00K |
| Net Income | -416.88M | -392.69M | -64.74M | -66.39M |
| Diluted EPS | -50.00 | -46.60 | -7.60 | -152.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 3.47B | 3.09B | 2.79B | 2.20B |
| Current Assets | - | 3.24B | 2.93B | 2.65B | 2.12B |
| Cash & Equivalents | - | 673.67M | 603.52M | 462.29M | 510.97M |
| Inventory | - | 1.50B | 1.42B | 1.39B | 998.47M |
| Receivables | - | 488.88M | 536.82M | 413.10M | 259.69M |
| Total Liabilities | - | 2.83B | 2.81B | 2.41B | 1.99B |
| Current Liabilities | - | 2.73B | 2.75B | 2.34B | 1.95B |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 344.19M | 443.23M | 256.77M | 236.71M |
| Total Equity | - | -414.60M | -583.45M | -642.64M | -702.23M |
| Shares Outstanding | - | 169.37M | 171.38M | 173.21M | 176.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -23.15M | -447.24M | 263.02M | 119.14M |
| Investing Cash Flow | - | -47.17M | 151.74M | 37.38M | -53.72M |
| Financing Cash Flow | - | 22.73M | 205.98M | -406.24M | -21.19M |
| Capital Expenditure | - | -31.69M | -9.82M | -15.20M | -4.45M |
| Free Cash Flow | - | -54.84M | -457.07M | 247.82M | 114.69M |
| Net Change in Cash | - | -47.59M | -89.52M | -105.84M | 44.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 6.2% | 5.7% | 5.8% | 5.8% |
| Operating Margin % | -2.7% | -2.3% | 0.0% | -0.0% |
| Net Margin % | -3.1% | -2.6% | -0.4% | -0.5% |
| ROE % | 100.5% | 67.3% | 10.1% | 9.5% |
| ROCE % | -49.6% | -101.8% | 0.5% | -1.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Renaissance Technologies, LLC | 0.25% | 13.01K | $50.10K |
| 2 | Serenus Wealth Advisors, LLC | 0.08% | 4.32K | $16.63K |
| 3 | UBS Group AG | - | 100 | $384 |
| 4 | Citigroup Inc. | - | 207 | $796 |
| 5 | Rhumbline Advisers | - | 22 | $84 |
| 6 | JPMORGAN CHASE & CO | - | 52 | $200 |
| 7 | Morgan Stanley | - | 113 | $435 |
| 8 | SBI Securities Co., Ltd. | - | 149 | $573 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for YI
YI — Frequently Asked Questions
What is the current share price of 111, Inc. (YI)?
As of 2026-08-02 19:16 PDT, 111, Inc. (YI) trades at $3.85 on NasdaqGM. Its 52-week range is $2.56 to $8.38.
What is the market capitalisation of YI?
111, Inc. (YI) has a market capitalisation of $33.87M on NasdaqGM.
What is the P/E ratio of YI?
YI trades at a trailing price-to-earnings (P/E) ratio of -0.50. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is -0.31.
What is the return on equity (ROE) of YI?
YI has a return on equity (ROE) of -14.84%. Its return on capital employed (ROCE) is 5.30%.
Is YI a good stock to buy?
This page provides a data-driven analysis of 111, Inc. (YI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.